Transthyretin: Osteoarticular and Cardiovascular Diseases: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Cell Biology
Contributor:
Elżbieta Wieczorek

Transthyretin (TTR) is a tetrameric protein transporting hormones in the plasma and brain, which has many other activities that have not been fully acknowledged. TTR is a positive indicator of nutrition status and is negatively correlated with inflammation. TTR is a neuroprotective and oxidative-stress-suppressing factor.

  • heart disease
  • atherosclerosis
  • thrombosis
  • COVID-19
  • amyloid
  • biomineralization
  • ROS

1. TTR Structure and Major Functions

Human TTR (UniProtKB, P02766) is a homotetrameric, slightly acidic (isoelectric point of 5.3) protein with a molecular weight of 55 kDa (Protparam, https://web.expasy.org/protparam/ ) that binds and transports thyroid hormones and retinol in the plasma and cerebrospinal fluid (CSF) [1][2]. TTR is synthesized predominantly in the liver and choroid plexus [3][4]. However, TTR is also present in kidneys, the pineal gland, and in certain types of cells, such as neurons, retinal pigment epithelium, or pancreatic island cells [2][5][6][7][8][9]. TTR expression in the liver is controlled by hepatocyte nuclear factors [10]. In the brain, TTR synthesis is enhanced by heat shock factor 1 [11] and mitochondrial transcription factor A (TFAM) [12]. Stress and steroid hormones, phenylalanine, and its metabolites also regulate TTR expression [9][13][14]. The central ligand-binding channel is formed when four TTR monomers assemble into the complex [15]. This hydrophobic cavity is able to accommodate up to two thyroxine molecules. However, due to negative cooperativity, TTR carries only a single thyroxine molecule [16]. In plasma, human TTR binds, with intermediate affinity, 15–20% of the thyroid hormone pool, complementing the transport provided by thyroxine-binding globulin and albumin. However, TTR is the major thyroid hormone-binding protein in CSF [17][18]. This binding protects thyroid hormones from adsorption on lipid phases; therefore, almost all hormone molecules circulate in a protein-bound form [18]. On the other hand, only a small population of TTR molecules carry the ligand because TTR concentration greatly exceeds the thyroid hormone level in both plasma and CSF [17][19][20][21]. The central channel of TTR can also tolerate multiple other natural ligands, including lutein and other carotenoids, curcumin, polyphenols (resveratrol), norepinephrine oxidation products, and other compounds [1][22][23][24]. TTR also distributes retinol complexed with retinol-binding protein (RBP), and the binding stoichiometry is 1:1:1 [25]. RBP binding is able to influence physiological function of TTR. RBP abrogates the binding of soluble TTR to receptor for advanced glycation end products (RAGE) [26]. Aggregated (fibrillar) TTR activates nuclear factor κB through interaction with RAGE and induces inflammatory and apoptotic responses [26]. Additionally, the interaction of TTR with perlecan, a component of the basement membrane, is negatively influenced by RBP [27]. Approximately 1–2% of TTR molecules circulate in the plasma in association with high density lipoproteins (HDL) due to the binding to apolipoprotein A1 (ApoA1) [28]. However, the interaction of TTR with ApoA1 is not affected by RBP [28]. The neurogenic effects of TTR are also not dependent on its ligands: RBP and thyroxine [29]. TTR has neuroprotective functions and/or is a stress response factor in various adverse conditions, including ischemia, Alzheimer’s disease (AD), Crohn’s disease, osteoarthritis, and preeclampsia [29][30][31][32][33]. Interestingly, RBP, by stabilizing TTR structure, reduces the inhibitory effect of TTR on Aβ aggregation [34]. In addition to neuroprotection and neurogenic activity, TTR is engaged in insulin secretion, autophagy, memory, and behavior [35][36][37][38][39]. TTR is a diagnostic marker positively correlated with nutrition, for both protein and glucose metabolism, and negatively correlated with acute inflammatory states [40]. Importantly, TTR is a Zn 2+ -dependent protease (also active in the presence of Mn 2+ , Fe 3+ , and Co 2+ ) that cleaves ApoA1, neuropeptide Y (NPY), and amyloid β (Aβ) peptide [41][42][43].

2. Involvement of TTR in Biomineralization

Proteomic analysis identified TTR as one of the proteins specifically associated with mammillary cones and important for the initial phase of eggshell biomineralization in chicken [44]. Investigation of the ability of TTR to influence the formation and morphology of calcium carbonate crystals demonstrated that extensive and amorphous deposits of human TTR are associated with crystals with unique morphology [45]. Additionally, various amyloid-like TTR forms, which remodel crystal faces, were present on the inner and outer surfaces of the crystals [45]. Morphology of large crystals is strikingly similar to that of the crystals obtained in the presence of MRCP20 protein, which is involved in biomineralization of the cement of barnacle Megabalanus rosa [45][46][47]. MRCP20 initiates the formation of amyloid-like fibrils on the surface of mineral crystals through stable β-sheet motives [48]. Some calcium carbonate crystals grown in the presence of TTR were small and rod-shaped [45]. Rod-shaped structures were also observed in the barnacle cement [49], indicating functional similarity between MRCP20 and TTR. Currently available information about the nucleation stage of biomineralization indicates the importance of the amyloid and disordered protein components in the formation of the polymer-induced liquid phase (PILP) in the presence of ions [50][51]. Thus, it was postulated that TTR amyloid may play a functional role in biomineralization, e.g., in the cement line, which constitutes the mineralization front between the subchondral bone and calcified cartilage [45][52].

3. TTR Interconnection with Inflammation

The deposition of aggregated proteins (including fibrin) activates tPA and factor XII [53]. tPA activation directly leads to an increase in plasmin levels (an increase in fibrinolytic activity). On the other hand, the activation of factor XII leads to the activation of the intrinsic coagulation pathway and results in the formation of bradykinin, a vasoactive peptide that promotes/induces multiple inflammatory responses [53].

On the other hand, properly folded TTR is a negative marker of inflammation and a positive marker of nutrition status, guarding the homeostasis of protein synthesis and breakdown [32][40]. However, elevated ROS, oxidative modifications, and aging negatively affect the structural stability of proteins in general, and TTR in particular, and lead to TTR aggregation [54][55][56][57]. In turn, TTR amyloid induces a cytotoxic response that involves ER stress, dysregulation of Ca 2+ balance, induction of UPR, upregulation of MMPs, apoptosis, and binding of membrane lipids [58][59][60][61][62]. Consequently, TTR amyloid contributes to oxidative stress and progression of inflammation [63][64][65][66]. In the plasma of FAP patients, the levels of cytokines (such as TNF-α, IL-1β, IL-8, IL-33, IFN-β, IL-10, and IL-12) are altered compared to those in healthy individuals [66]. Changes in cytokine levels were also observed in asymptomatic FAP patients, indicating that the induction of inflammation precedes amyloid fibril deposition [66].

Stabilization of proper TTR structure reduces cytotoxicity induced by TTR aggregates and improves survival of patients with ATTR CA [67][68]. However, the factors that reduce oxidative stress, such as tauroursodeoxycholic acid (TUDCA), were also shown to lead to a reduction in toxic aggregates of TTR [65]. TUDCA does not affect the stability of TTR in vitro, suggesting that the association of TTR with oxidative stress and inflammation is indirect and bidirectional, and that oxidative stress leads to TTR destabilization and amyloid formation [65]. This bidirectional relationship between amyloid and inflammation also occurs in AD. Aβ peptide deposits induce immune response, and molecules involved in inflammatory processes can increase the formation of Aβ [69][70]. Interestingly, inflammatory processes that lead to Aβ deposition are induced by peripheral plasmin [69]. Chronic inflammation leads to amyloidosis, and amyloid activates immune signaling [71][69][70]. Since inflammation, in turn, accelerates protein aggregation, this interconnection drives vicious cycle 3 ( Figure 1 B).

In blood exposed to inflammatory concentrations of hypochlorous acid, the oxidation of amino acid residues and dityrosine crosslinking of TTR with other plasma proteins (such as α1-antitrypsin, haptoglobin, and albumin) was detected [57]. HMW aggregates of oxidized proteins also include α, β, and γ fibrinogen chains, apolipoprotein A1, and complement C3. In vivo, hypochlorous acid is produced by myeloperoxidase (MPO), which is present in mammalian neutrophils, monocytes, and some subtypes of tissue macrophages [62][72]. MPO is the key enzyme in the host innate immune defense against pathogen infection [62][72]. Elevated levels of MPO activity in the plasma are observed in myocardial infarction and in ACS, and high MPO concentrations are associated with major adverse cardiovascular events in patients with CAD [62][73][74]. The yin and yang action/dual nature of MPO is manifested by the destruction of invading pathogens and MPO involvement in disease progression and harmful effects on the host tissues [62].

4. TTR Regulation of Angiogenesis

Transcriptome analysis of human retinal endothelial cells (hRECs) in diabetic retinopathy (DR) revealed the regulatory network of protective functions of TTR, implying that TTR co-ordinates oxidative stress, inflammation signaling, autophagy, and apoptosis in DR [75]. DR is a serious microvascular complication of diabetes mellitus caused by hyperglycemia and hypoxia due to metabolic imbalance. Under hypoxic conditions, TTR interacts with and upregulates GRP78 and acts as a trigger of apoptosis of hRECs, which leads to the suppression of neovascularization [21][76]. Under hyperglycemic conditions, TTR represses angiogenesis by inhibiting the proliferation of hRECs through the tyrosine protein kinase receptor 2 (Tie 2) signaling pathway [77]. TTR also suppresses the proliferation of hRECs by long noncoding RNA (lncRNA) MEG3 in the miR-223-3p/FBXW7/Notch1 signaling pathway [78][79]. Therefore, TTR regulates lncRNAs to repress vascular leakage in the retina [75][79]. TTR is also able to regulate and interact with vascular endothelial growth factor [77][80].

Neovascularisation plays an important role in wound healing and atherosclerosis [81][82]. HDL transports miR-223 and other miRNAs [83][84], and signaling of multiple noncoding RNAs is involved in the progression of atherosclerosis [85]. Some lncRNAs are involved in VSMCs phenotype switching. For example, MALAT1/miR-204/SMAD4 regulates osteoblastic differentiation of human aortic valve interstitial cells in CAVD, and TUG1/miR-204-5p promotes osteoblastic differentiation by upregulating Runx2 in aortic valve calcification [85]. lncMEG3 is one of the lncRNAs responsible for pathological cardiac remodeling in atherosclerosis and ECM reconstruction [86], and MEG3 was shown to be downregulated in CAD [87]. The MEG3/miR-223/NLRP3 inflammasome pathway has been shown to enhance inflammatory cell death (pyroptosis) in human aortic endothelial cells [88]. It is of interest to determine whether TTR (directly or indirectly through HDL) regulates the MEG3/miR-223-3p/FBXW7/Notch1 signaling pathway in atherosclerosis.

This entry is adapted from the peer-reviewed paper 10.3390/cells10071768

References

  1. Liz, M.A.; Mar, F.M.; Franquinho, F.; Sousa, M.M. Aboard transthyretin: From transport to cleavage. IUBMB Life 2010, 62, 429–435.
  2. Buxbaum, J.N.; Reixach, N. Transthyretin: The servant of many masters. Cell. Mol. Life Sci. 2009, 66, 3095–3101.
  3. Richardson, S.J. Evolutionary changes to transthyretin: Evolution of transthyretin biosynthesis. FEBS J. 2009, 276, 5342–5356.
  4. Aleshire, S.L.; Bradley, C.A.; Richardson, L.D.; Parl, F.F. Localization of human prealbumin in choroid plexus epithelium. J. Histochem. Cytochem. 1983, 31, 608–612.
  5. Bailey, M.J.; Coon, S.L.; Carter, D.A.; Humphries, A.; Kim, J.-S.; Shi, Q.; Gaildrat, P.; Morin, F.; Ganguly, S.; Hogenesch, J.B.; et al. Night/Day Changes in Pineal Expression of >600 Genes. J. Biol. Chem. 2009, 284, 7606–7622.
  6. Cavallaro, T.; Martone, R.; Dwork, A.J.; Schon, E.A.; Herbert, J. The retinal pigment epithelium is the unique site of transthyretin synthesis in the rat eye. Investig. Ophthalmol. Vis. Sci. 1990, 31, 497–501.
  7. Refai, E.; Dekki, N.; Yang, S.-N.; Imreh, G.; Cabrera, O.; Yu, L.; Yang, G.; Norgren, S.; Rossner, S.M.; Inverardi, L.; et al. Transthyretin constitutes a functional component in pancreatic -cell stimulus-secretion coupling. Proc. Natl. Acad. Sci. USA 2005, 102, 17020–17025.
  8. Su, Y.; Jono, H.; Misumi, Y.; Senokuchi, T.; Guo, J.; Ueda, M.; Shinriki, S.; Tasaki, M.; Shono, M.; Obayashi, K.; et al. Novel function of transthyretin in pancreatic alpha cells. FEBS Lett. 2012, 586, 4215–4222.
  9. Wakasugi, S.; Maeda, S.; Shimada, K. Structure and Expression of the Mouse Prealbumin Gene. J. Biochem. 1986, 100, 49–58.
  10. Costa, R.H.; Grayson, D.R.; Darnell, J.E. Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes. Mol. Cell. Biol. 1989, 9, 1415–1425.
  11. Wang, X.; Cattaneo, F.; Ryno, L.; Hulleman, J.; Reixach, N.; Buxbaum, J.N. The Systemic Amyloid Precursor Transthyretin (TTR) Behaves as a Neuronal Stress Protein Regulated by HSF1 in SH-SY5Y Human Neuroblastoma Cells and APP23 Alzheimer’s Disease Model Mice. J. Neurosci. 2014, 34, 7253–7265.
  12. Oka, S.; Leon, J.; Sakumi, K.; Ide, T.; Kang, N.; LaFerla, F.M.; Nakabeppu, Y. Human mitochondrial transcriptional factor A breaks the mitochondria-mediated vicious cycle in Alzheimer’s disease. Sci. Rep. 2016, 6, 37889.
  13. Park, J.-W.; Lee, M.H.; Choi, J.-O.; Park, H.-Y.; Jung, S.-C. Tissue-specific activation of mitogen-activated protein kinases for expression of transthyretin by phenylalanine and its metabolite, phenylpyruvic acid. Exp. Mol. Med. 2010, 42, 105–115.
  14. Martinho, A.; Gonsalves, J.; Costa, M.; Santos, C.R. Stress and glucocorticoids increase transthyretin expression in rat choroid plexus via mineralocorticoid and glucocorticoid receptorse. J. Mol. Neurosci. 2012, 48, 1–13.
  15. Blake, C.C.F.; Burridge, J.M.; Oatley, S.J. X-Ray Analysis of Thyroid Hormone Binding to Prealbumin. Biochem. Soc. Trans. 1978, 6, 1114–1118.
  16. Ferguson, R.F.; Edelhoch, H.; Saroff, H.; Robins, J.A.; Cahnmann, H.J. Negative cooperativity in the binding of thyroxine to human serum prealbumin. Biochemistry 1875, 14, 282–289.
  17. Hagen, G.A.; Elliott, W.J. Transport of Thyroid Hormones in Serum and Cerebrospinal Fluid. J. Clin. Endocrinol. Metab. 1973, 37, 415–422.
  18. Rabah, S.A.; Gowan, I.L.; Pagnin, M.; Osman, N.; Richardson, S.J. Thyroid Hormone Distributor Proteins During Development in Vertebrates. Front. Endocrinol. 2019, 10, 506.
  19. Benvenga, S.; Bartalena, L.; Antonelli, A.; Calzi, L.L.; Di Pasquale, G.; Trimarchi, F.; Pinchera, A. Radioimmunoassay for human thyroxine-binding prealbumin. Ann. Clin. Lab. Sci. 1986, 16, 231–240.
  20. Weisner, B.; Roethig, H.-J. The Concentration of Prealbumin in Cerebrospinal Fluid (CSF), Indicator of CSF Circulation Disorders. Eur. Neurol. 1983, 22, 96–105.
  21. Gião, T.; Saavedra, J.; Cotrina, E.; Quintana, J.; Llop, J.; Arsequell, G.; Cardoso, I. Undiscovered Roles for Transthyretin: From a Transporter Protein to a New Therapeutic Target for Alzheimer’s Disease. Int. J. Mol. Sci. 2020, 21, 2075.
  22. Ferreira, N.; Saraiva, M.J.; Almeida, M.R. Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis. Int. J. Mol. Sci. 2019, 20, 1287.
  23. Pullakhandam, R.; Srinivas, P.; Nair, M.K.; Reddy, G.B. Binding and stabilization of transthyretin by curcumin. Arch. Biochem. Biophys. 2009, 485, 115–119.
  24. Bourgault, S.; Choi, S.; Buxbaum, J.N.; Kelly, J.W.; Price, J.L.; Reixach, N. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem. Biophys. Res. Commun. 2011, 410, 707–713.
  25. Monaco, H.L.; Rizzi, M.; Coda, A. Structure of a complex of two plasma proteins: Transthyretin and retinol-binding protein. Science 1995, 268, 1039–1041.
  26. Sousa, M.; Du Yan, S.; Stern, D.; Saraiva, M.J. Interaction of the Receptor for Advanced Glycation End Products (RAGE) with Transthyretin Triggers Nuclear Transcription Factor kB (NF-kB) Activation. Lab. Investig. 2000, 80, 1101–1110.
  27. Smeland, S.; Kolset, S.O.; Lyon, M.; Norum, K.R.; Blomhoff, R. Binding of perlecan to transthyretin qin vitro. Biochem. J. 1997, 326, 829–836.
  28. Sousa, M.; Berglund, L.; Saraiva, M.J. Transthyretin in high density lipoproteins: Association with apolipoprotein A-I. J. Lipid Res. 2000, 41, 58–65.
  29. Gomes, J.; Nogueira, R.S.; Vieira, M.; Santos, S.D.; Ferraz-Nogueira, J.P.; Relvas, J.B.; Saraiva, M.J. Transthyretin provides trophic support via megalin by promoting neurite outgrowth and neuroprotection in cerebral ischemia. Cell Death Differ. 2016, 23, 1749–1764.
  30. Schwarzman, A.L.; Gregori, L.; Vitek, M.P.; Lyubski, S.; Strittmatter, W.J.; Enghilde, J.J.; Bhasin, R.; Silverman, J.; Weisgraber, K.H.; Coyle, P.K. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc. Natl. Acad. Sci. USA 1994, 91, 8368–8372.
  31. Li, X.; Song, Y.; Sanders, C.R.; Buxbaum, J.N.; Diego, S.; Squibb, B.; Development, B.P.; Medicine, E.; Torrey, N.; Road, P.; et al. Transthyretin Suppresses Amyloid-β secretion by Interfering with Processing of The Amyloid-β Precursor Protein. J. Alzheimers Dis. 2016, 52, 1263–1275.
  32. Santos, S.D.; Lambertsen, K.L.; Clausen, B.H.; Akinc, A.; Alvarez, R.; Finsen, B.; Saraiva, M.J. CSF transthyretin neuroprotection in a mouse model of brain ischemia. J. Neurochem. 2010, 115, 1434–1444.
  33. Kalkunte, S.S.; Neubeck, S.; Norris, W.E.; Cheng, S.-B.; Kostadinov, S.; Hoang, D.V.; Ahmed, A.; von Eggeling, F.; Shaikh, Z.; Padbury, J.; et al. Transthyretin Is Dysregulated in Preeclampsia, and Its Native Form Prevents the Onset of Disease in a Preclinical Mouse Model. Am. J. Pathol. 2013, 183, 1425–1436.
  34. Mangrolia, P.; Murphy, R.M. Retinol-Binding Protein Interferes with Transthyretin-Mediated β-Amyloid Aggregation Inhibition. Biochemistry 2018, 57, 5029–5040.
  35. Fleming, C.E.; Saraiva, M.J.; Sousa, M.M. Transthyretin enhances nerve regeneration. J. Neurochem. 2007, 103, 831–839.
  36. Cascella, R.; Conti, S.; Mannini, B.; Li, X.; Buxbaum, J.N.; Tiribilli, B.; Chiti, F.; Cecchi, C. Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2013, 1832, 2302–2314.
  37. Liz, M.A.; Coelho, T.; Bellotti, V.; Fernandez-Arias, M.I.; Mallaina, P.; Obici, L. A Narrative Review of the Role of Transthyretin in Health and Disease. Neurol. Ther. 2020, 9, 395–402.
  38. Sousa, J.; Marques, F.; Dias-Ferreira, E.; Cerqueira, J.; Sousa, N.; Palha, J.A. Transthyretin influences spatial reference memory. Neurobiol. Learn. Mem. 2007, 88, 381–385.
  39. Vieira-Coelho, M.A.; Saraiva, M.J. Transthyretin regulates hippocampal 14-3-3ζ protein levels. FEBS Lett. 2013, 587, 1482–1488.
  40. Ingenbleek, Y.; Bernstein, L.H. Plasma Transthyretin as a Biomarker of Lean Body Mass and Catabolic States. Adv. Nutr. 2015, 6, 572–580.
  41. Liz, M.A.; Faro, C.J.; Saraiva, M.J.; Sousa, M.M. Transthyretin, a new cryptic protease. J. Biol. Chem. 2004, 279, 21431–21438.
  42. Liz, M.A.; Leite, S.C.; Juliano, L.; Saraiva, M.J.; Damas, A.M.; Bur, D.; Sousa, M.M. Transthyretin is a metallopeptidase with an inducible active site. Biochem. J. 2012, 443, 769–778.
  43. Costa, A.R.; Silva, F.; Saraiva, M.J.; Cardoso, I. Transthyretin Protects against A-Beta Peptide Toxicity by Proteolytic Cleavage of the Peptide: A Mechanism Sensitive to the Kunitz Protease Inhibitor. PLoS ONE 2008, 3, e2899.
  44. Rose-Martel, M.; Smiley, S.; Hincke, M.T. Novel identification of matrix proteins involved in calcitic biomineralization. J. Proteom. 2015, 116, 81–96.
  45. Wieczorek, E.; Chitruń, A.; Ożyhar, A. Destabilised human transthyretin shapes the morphology of calcium carbonate crystals. Biochim. Biophys. Acta (BBA) Gen. Subj. 2019, 1863, 313–324.
  46. Mori, Y.; Urushida, Y.; Nakano, M.; Uchiyama, S.; Kamino, K. Calcite-specific coupling protein in barnacle underwater cement. FEBS J. 2007, 274, 6436–6446.
  47. So, C.R.; Liu, J.; Fears, K.P.; Leary, D.H.; Golden, J.P.; Wahl, K.J. Self-Assembly of Protein Nanofibrils Orchestrates Calcite Step Movement through Selective Nonchiral Interactions. ACS Nano 2015, 9, 5782–5791.
  48. Mohanram, H.; Kumar, A.; Verma, C.S.; Pervushin, K.; Miserez, A. Three-dimensional structure of Megabalanus rosa Cement Protein 20 revealed by multi-dimensional NMR and molecular dynamics simulations. Philos. Trans. R. Soc. B Biol. Sci. 2019, 374, 20190198.
  49. Sullan, R.M.A.; Gunari, N.; Tanur, A.E.; Chan, Y.; Dickinson, G.H.; Orihuela, B.; Rittschof, D.; Walker, G.C. Nanoscale structures and mechanics of barnacle cement. Biofouling 2009, 25, 263–275.
  50. Evans, J.S. “Liquid-like” biomineralization protein assemblies: A key to the regulation of non-classical nucleation. CrystEngComm 2013, 15, 8388–8394.
  51. Rani, R.S.; Saharay, M. Molecular dynamics simulation of protein-mediated biomineralization of amorphous calcium carbonate. RSC Adv. 2019, 9, 1653–1663.
  52. Zhang, Y.; Wang, F.; Tan, H.; Chen, G.; Guo, L.; Yang, L. Analysis of the Mineral Composition of the Human Calcified Cartilage Zone. Int. J. Med Sci. 2012, 9, 353–360.
  53. Gebbink, M.F.; Bouma, B.; Maas, C.; Bouma, B.N. Physiological responses to protein aggregates: Fibrinolysis, coagulation and inflammation (new roles for old factors). FEBS Lett. 2009, 583, 2691–2699.
  54. Zhang, Q.; Kelly, J.W. Cys10 Mixed Disulfides Make Transthyretin More Amyloidogenic under Mildly Acidic Conditions. Biochemistry 2003, 42, 8756–8761.
  55. Zhao, L.; Buxbaum, J.N.; Reixach, N. Age-Related Oxidative Modifications of Transthyretin Modulate Its Amyloidogenicity. Biochemistry 2013, 52, 1913–1926.
  56. Poulsen, K.; Mc Bahl, J.; Simonsen, A.H.; Hasselbalch, S.G.; Heegaard, N.H. Distinct transthyretin oxidation isoform profile in spinal fluid from patients with Alzheimer’s disease and mild cognitive impairment. Clin. Proteom. 2014, 11, 12.
  57. Colombo, G.; Clerici, M.; Altomare, A.; Rusconi, F.; Giustarini, D.; Portinaro, N.; Garavaglia, M.L.; Rossi, R.; Dalle-Donne, I.; Milzani, A.D.G. Thiol oxidation and di-tyrosine formation in human plasma proteins induced by inflammatory concentrations of hypochlorous acid. J. Proteom. 2017, 152, 22–32.
  58. Tanaka, K.; Essick, E.E.; Doros, G.; Tanriverdi, K.; Connors, L.H.; Seldin, D.C.; Sam, F. Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis. J. Am. Heart Assoc. 2013, 2, e005868.
  59. Martins, D.; Moreira, J.; Gonçalves, N.P.; Saraiva, M.J. MMP-14 overexpression correlates with the neurodegenerative process in familial amyloidotic polyneuropathy. Dis. Model. Mech. 2017, 10, 1253–1260.
  60. Dubrey, S.W.; Cha, K.; Skinner, M.; LaValley, M.; Falk, R.H. Familial and primary (AL) cardiac amyloidosis: Echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997, 78, 74–82.
  61. Poltash, M.L.; Shirzadeh, M.; McCabe, J.W.; Moghadamchargari, Z.; Laganowsky, A.; Russell, D.H. New insights into the metal-induced oxidative degradation pathways of transthyretin. Chem. Commun. 2019, 55, 4091–4094.
  62. Arnhold, J. The Dual Role of Myeloperoxidase in Immune Response. Int. J. Mol. Sci. 2020, 21, 8057.
  63. Fong, V.H.; Vieira, A. Cytotoxic Effects of Transthyretin Aggregates in an Epidermoid Cell Line. Pathobiology 2017, 84, 218–222.
  64. Sousa, M.M.; Amaral, J.; Guimarães, A.; Saraiva, M.J. Upregulation of the Extracellular Matrix Remodeling Genes, Biglycan, Neutrophil Gelatinase-Associated Lipocalin and Matrix Metalloproteinase-9 in Familial Amyloid Polyneuropathy. Amyloid Amyloidosis 2004, 20, 320–322.
  65. Macedo, B.; Batista, A.R.; Ferreira, N.; Almeida, M.; Saraiva, M.J. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2008, 1782, 517–522.
  66. Azevedo, E.P.; Guimaraes-Costa, A.B.; Bandeira-Melo, C.; Chimelli, L.; Waddington-Cruz, M.; Saraiva, E.M.; Palhano, F.L.; Foguel, D. Inflammatory profiling of patients with familial amyloid polyneuropathy. BMC Neurol. 2019, 19, 146.
  67. Park, G.Y.; Jamerlan, A.; Shim, K.H.; An, S.S.A. Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases. Int. J. Mol. Sci. 2019, 20, 2982.
  68. Maurer, M.S.; Schwartz, J.H.; Gundapaneni, B.; Elliott, P.M.; Merlini, G.; Waddington-Cruz, M.; Kristen, A.V.; Grogan, M.; Witteles, R.; Damy, T.; et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N. Engl. J. Med. 2018, 379, 1007–1016.
  69. Baker, S.K.; Chen, Z.-L.; Norris, E.; Revenko, A.S.; MacLeod, A.R.; Strickland, S. Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 2018, 115, E9687–E9696.
  70. Azevedo Estefania, P.; Foguel, D. The Role of Inflammation in Amyloid Diseasesitle. In Amyloid Diseases; IntechOpen: London, UK, 2018.
  71. Parry, T.L.; Melehani, J.; Ranek, M.J.; Willis, M. Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure. Front. Cardiovasc. Med. 2015, 2, 25.
  72. Klebanoff, S.J.; Kettle, T.; Rosen, H.; Winterbourn, C.C.; Nauseef, W.M. Myeloperoxidase: A front-line defender against phagocytosed microorganisms. J. Leukoc. Biol. 2013, 93, 185–198.
  73. Tang, W.W.; Wu, Y.; Nicholls, S.; Hazen, S.L. Plasma Myeloperoxidase Predicts Incident Cardiovascular Risks in Stable Patients Undergoing Medical Management for Coronary Artery Disease. Clin. Chem. 2011, 57, 33–39.
  74. Baldus, S.; Heeschen, C.; Meinertz, T.; Zeiher, A.M.; Eiserich, J.P.; Münzel, T.; Simoons, M.L.; Hamm, C.W. Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes. Circulation 2003, 108, 1440–1445.
  75. Shao, J.; Zhang, Y.; Fan, G.; Xin, Y.; Yao, Y. Transcriptome analysis identified a novel 3-LncRNA regulatory network of transthyretin attenuating glucose induced hRECs dysfunction in diabetic retinopathy. BMC Med Genom. 2019, 12, 134.
  76. Shao, J.; Yin, Y.; Yin, X.; Ji, L.; Xin, Y.; Zou, J.; Yao, Y. Transthyretin Exerts Pro-Apoptotic Effects in Human Retinal Microvascular Endothelial Cells Through a GRP78-Dependent Pathway in Diabetic Retinopathy. Cell. Physiol. Biochem. 2017, 43, 788–800.
  77. Shao, J.; Yao, Y. Transthyretin represses neovascularization in diabetic retinopathy. Mol. Vis. 2016, 22, 1188–1197.
  78. Shao, J.; Fan, G.; Yin, X.; Gu, Y.; Wang, X.; Xin, Y.; Yao, Y. A novel transthyretin/STAT4/miR-223-3p/FBXW7 signaling pathway affects neovascularization in diabetic retinopathy. Mol. Cell. Endocrinol. 2019, 498, 110541.
  79. Fan, G.; Gu, Y.; Zhang, J.; Xin, Y.; Shao, J.; Giampieri, F.; Battino, M. Transthyretin Upregulates Long Non-Coding RNA MEG3 by Affecting PABPC1 in Diabetic Retinopathy. Int. J. Mol. Sci. 2019, 20, 6313.
  80. Cehofski, L.J.; Kruse, A.; Alsing, A.N.; Nielsen, J.E.; Pedersen, S.; Kirkeby, S.; Honoré, B.; Vorum, H. Intravitreal bevacizumab upregulates transthyretin in experimental branch retinal vein occlusion. Mol. Vis. 2018, 24, 759–766.
  81. Badimon, L.; Vilahur, G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J. Intern. Med. 2014, 276, 618–632.
  82. Camaré, C.; Pucelle, M.; Nègre-Salvayre, A.; Salvayre, R. Angiogenesis in the atherosclerotic plaque. Redox Biol. 2017, 12, 18–34.
  83. Kudinov, V.A.; Alekseeva, O.Y.; Torkhovskaya, T.I.; Baskaev, K.K.; Artyushev, R.I.; Saburina, I.N.; Markin, S.S. High-Density Lipoproteins as Homeostatic Nanoparticles of Blood Plasma. Int. J. Mol. Sci. 2020, 21, 8737.
  84. Tabet, F.; Vickers, K.C.; Torres, L.F.C.; Wiese, C.; Shoucri, B.M.; Lambert, G.; Catherinet, C.; Prado-Lourenco, L.; Levin, M.G.; Thacker, S.; et al. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat. Commun. 2014, 5, 3292.
  85. Navarro, E.; Mallén, A.; Cruzado, J.M.; Torras, J.; Hueso, M. Unveiling ncRNA regulatory axes in atherosclerosis progression. Clin. Transl. Med. 2020, 9, e5.
  86. Zhou, H.; Wang, B.; Yang, Y.-X.; Jia, Q.-J.; Zhang, A.; Qi, Z.-W.; Zhang, J.-P. Long Noncoding RNAs in Pathological Cardiac Remodeling: A Review of the Update Literature. BioMed Res. Int. 2019, 2019, 7159592.
  87. Wu, Z.; He, Y.; Li, N.; Fang, X.; Shang, T.; Zhang, H.; Zheng, X. Long noncoding RNA MEG3 suppressed endothelial cell proliferation and migration through regulating miR-21. Am. J. Transl. Res. 2017, 9, 3326–3335.
  88. Zhang, Y.; Liu, X.; Bai, X.; Lin, Y.; Li, Z.; Fu, J.; Li, M.; Zhao, T.; Yang, H.; Xu, R.; et al. Melatonin prevents endothelial cell pyroptosis via regulation of long noncoding RNA MEG3/miR-223/NLRP3 axis. J. Pineal Res. 2018, 64, e12449.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback